Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ. Colombel JF, et al. Among authors: mantzaris gj. Aliment Pharmacol Ther. 2015 Apr;41(8):734-46. doi: 10.1111/apt.13139. Epub 2015 Mar 1. Aliment Pharmacol Ther. 2015. PMID: 25728587 Clinical Trial.
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.
Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tiong JHT, Steinberg J, Kruis W, Steinwurz F, Ahuja V, Ng SC, Rubin DT, Colombel JF, Gearry R; International Organization for Study of Inflammatory Bowel Diseases. Ananthakrishnan AN, et al. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):666-678. doi: 10.1016/S2468-1253(22)00021-8. Epub 2022 Apr 27. Lancet Gastroenterol Hepatol. 2022. PMID: 35487235 Review.
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
Kopylov U, Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF, Israeli E, Lakatos PL, Fiorino G, Cesarini M, Tsianos EV, Louis E, Ben-Horin S. Kopylov U, et al. Among authors: mantzaris gj. Aliment Pharmacol Ther. 2011 Feb;33(3):349-57. doi: 10.1111/j.1365-2036.2010.04523.x. Epub 2010 Dec 1. Aliment Pharmacol Ther. 2011. PMID: 21118397 Free article.
The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method.
Reinisch W, Chowers Y, Danese S, Dignass A, Gomollón F, Nielsen OH, Lakatos PL, Lees CW, Lindgren S, Lukas M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H. Reinisch W, et al. Among authors: mantzaris gj. Aliment Pharmacol Ther. 2013 Nov;38(9):1109-18. doi: 10.1111/apt.12493. Epub 2013 Sep 17. Aliment Pharmacol Ther. 2013. PMID: 24099472 Free PMC article.
Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines.
Gomollón F, Chowers Y, Danese S, Dignass A, Haagen Nielsen O, Lakatos PL, Lees CW, Lindgren S, Lukas M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H, Reinisch W. Gomollón F, et al. Among authors: mantzaris gj. Aliment Pharmacol Ther. 2014 Apr;39(7):743-4. doi: 10.1111/apt.12648. Aliment Pharmacol Ther. 2014. PMID: 24588280 No abstract available.
Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.
Bourreille A, Ignjatovic A, Aabakken L, Loftus EV Jr, Eliakim R, Pennazio M, Bouhnik Y, Seidman E, Keuchel M, Albert JG, Ardizzone S, Bar-Meir S, Bisschops R, Despott EJ, Fortun PF, Heuschkel R, Kammermeier J, Leighton JA, Mantzaris GJ, Moussata D, Lo S, Paulsen V, Panés J, Radford-Smith G, Reinisch W, Rondonotti E, Sanders DS, Swoger JM, Yamamoto H, Travis S, Colombel JF, Van Gossum A; World Organisation of Digestive Endoscopy (OMED) and the European Crohn's and Colitis Organisation (ECCO). Bourreille A, et al. Among authors: mantzaris gj. Endoscopy. 2009 Jul;41(7):618-37. doi: 10.1055/s-0029-1214790. Epub 2009 Jul 8. Endoscopy. 2009. PMID: 19588292 Free article. Review.
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
Siegel CA, Melmed GY, McGovern DP, Rai V, Krammer F, Rubin DT, Abreu MT, Dubinsky MC; International Organization for the Study of Inflammatory Bowel Disease (IOIBD); International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). Siegel CA, et al. Gut. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000. Epub 2021 Jan 20. Gut. 2021. PMID: 33472895 Free PMC article. No abstract available.
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Peyrin-Biroulet L, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798039 Free article. Clinical Trial.
[Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)].
Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, van Assche G. Dignass A, et al. Rev Gastroenterol Mex. 2014 Oct-Dec;79(4):263-89. doi: 10.1016/j.rgmx.2014.10.001. Epub 2014 Dec 6. Rev Gastroenterol Mex. 2014. PMID: 25487134 Free article. Review. Spanish. No abstract available.
158 results